U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
There have been three confirmed reports of post reinfusion hemolysis or hemoglobinuria in patients treated on the therakos cellex photopheresis system.
조치
Therakos sent an "URGENT PRODUCT CORRECTION NOTIFICATION" dated September 1, 2011 to all affected customers. The letter described the product, problem, and actions to be taken by the customers. Additionally, a Confirmation of Receipt was attached to the letter for customers to complete and return. Contact Therakos Technical Support at 1-877-865-6850 for questions regarding this notice.
Therakos Cellex Photopheresis System || CellexUSA & Cellex. || The photopheresis system is indicated for use in the ultraviolet-A (UVA) irradiation in the presence of the photoactive drug 8-methoxypsoralen (8-MOP) of extracorporeally circulating leukocyte-enriched blood in the palliative treatment of the skin manifestation of cutaneous T-cell lymphoma (CTCL) in person who have not been responsive to other forms of treatment. The Cellex procedural kits are designed to interface with the Cellex Photopheresis System to perform cell separation and photo activation in a single closed and sterile circuit. This is accomplished by use of an integrated centrifuge bowl and associated tubing for separation of whole blood into red blood cells, plasma, and buffy coat (leukocyte-enriched blood). All blood components are returned to the patient. The procedural kits are fully assembled as received by the customer and the customer is only required to place the components in the Cellex System to enable the system for use.